Showing results (171-180 of 399) with videos related to

Sort By:
Pageof 40
Journal of Medical Ethics|August 18, 2016
The role of law in decisions to withhold and withdraw life-sustaining treatment from adults who lack capacity: a cross-sectional studyBenjamin P White, Lindy Willmott, Gail Williams, et al.
The American Journal of Drug and Alcohol Abuse|February 14, 2022
Perceived access to cannabis and ease of purchasing cannabis in retail stores in Canada immediately before and one year after legalizationElle Wadsworth, Pete Driezen, Gary Chan, et al.
Developmental Medicine and Child Neurology|January 26, 2019
Cannabinoids for the treatment of spasticitySuzanne Nielsen, Bridin Murnion, Gabrielle Campbell, et al.
Drug and Alcohol Dependence|June 2, 2005
Age differentials in the impacts of reduced heroin: effects of a "heroin shortage" in NSW, AustraliaLouisa Degenhardt, Carolyn Day, Elizabeth Conroy, et al.
Addiction (Abingdon, England)|January 19, 2021
A first pass, using pre-history and contemporary history, at understanding why Australia and England have such different policies towards electronic nicotine delivery systems, 1970s-c. 2018Virginia Berridge, Wayne Hall, Suzanne Taylor, et al.
Addiction (Abingdon, England)|July 29, 2011
Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?Polly Ambermoon, Adrian Carter, Wayne Hall, et al.
Reproductive Health Matters|November 26, 2008
Analysis of socio-political and health practices influencing sex ratio at birth in Viet NamBang Nguyen Pham, Wayne Hall, Peter S Hill, et al.
Addictive Behaviors|October 25, 2008
Alcohol industry and government revenue derived from underage drinking by Australian adolescents 2005Christopher M Doran, Anthony P Shakeshaft, Wayne Hall, et al.
Drug and Alcohol Dependence|July 9, 2005
The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependenceLouisa Degenhardt, Elizabeth Conroy, Carolyn Day, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Cost-effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart diseaseLinda K Kemp, Christopher M Doran, Theo Vos, et al.
Pageof 40